We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Illustration

Researchers Create SARS-CoV-2 Clone to Aid Development of COVID-19 Antivirals and Vaccines

Researchers have applied a novel reverse genetics approach to create recombinant SARS-CoV-2, which is a cloned virus that behaves like the original virus both in cultured cells and hamsters, and will aid in the development of SARS-CoV-2 antivirals and vaccines. More...
13 Oct 2020
Illustration

New Research Supports Use of Hepatitis C Drug Sofosbuvir in Combination with Remdesivir to Treat COVID-19

Researchers have reported that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2 than Remdesivir-terminated RNA, supporting the use of the FDA-approved hepatitis C drug EPCLUSA - Sofosbuvir/Velpatasvir - in combination with other drugs in COVID-19 clinical trials. More...
13 Oct 2020
Illustration

Thermo Fisher Launches Two New SARS-CoV-2 Antibody Tests to Further Broaden COVID-19 Test Portfolio

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test, and the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG test. More...
13 Oct 2020
Illustration

Properly Designed COVID-19 Vaccine Can Induce Durable Antibody Response to SARS-CoV-2, Finds Studies

 Researchers have found that immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus are longer lasting in the blood and saliva of COVID-19 patients as compared to the short-lived IgM and IgA response. More...
12 Oct 2020
Illustration

Gilead’s Remdesivir Cuts COVID-19 Recovery Time by Five Days and Death Risk by 70% in “Gold Standard” Trial

Gilead Sciences (Foster City, CA, USA) has published final results from the double-blind, placebo-controlled, Phase 3 ACTT-1 trial of Veklury (remdesivir) that demonstrates treatment with its investigational antiviral resulted in a faster time to recovery than previously reported in adults hospitalized with mild-moderate or severe COVID-19. More...
12 Oct 2020
Image: LightStrike Germ-Zapping robot (Photo courtesy of Xenex)

Germ-Zapping Robot Deactivates SARS-CoV-2 on Surfaces in Two Minutes

A new disinfection robot that destroys hard-to-kill viruses, bacteria and superbugs in hard-to-clean places has been proven to deactivate SARS-CoV-2, the virus that causes COVID-19, on surfaces in two minutes. More...
12 Oct 2020
Image: New COVID-19 Test Uses Magnetic Beads to Detect SARS-CoV-2 Virus (Photo courtesy of NTNU)

New COVID-19 Test Uses Magnetic Beads to Detect SARS-CoV-2 Virus

A highly sensitive COVID-19 test, developed by researchers at the Norwegian University of Science and Technology (NTNU Trondheim, Norway), relies on magnetic nanoparticles to extract viral RNA. More...
12 Oct 2020
Gold Member
12-Channel ECG
CM1200B
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Digital Radiographic System
OMNERA 300M
New
Documentation System For Blood Banks
HettInfo II